Pharma News

A new breed of mosquitoes laden with bacteria has proven capable of controlling the spread of dengue fever and the Zika virus, said Vietnam's health officials on Monday.

A diet rich in a fatty acid that is essential for nutrition and found in grapeseed and other oils but not in olive oil may lower the risk of heart disease and diabetes, suggests a study.

Researchers have found that a blood test may be able to sound early warning bells that patients with advanced melanoma skin cancer are suffering from relapse.

Obesity and eating fatty food are significant risk factors for many types of cancer. A new study has revealed that a high-fat diet makes the cells of the intestinal lining in the gut more likely to become cancerous.

Common asthma symptoms are associated with increased levels of stress and anxiety in teens, a study has found.A study by Henry Ford Hospital in Detroit city of Michigan state in the US has found in a small study of 38 asthma patients aged 14-17, that their average scores for stress and anxiety levels were higher than those seen in the general population.

Consuming foods and beverages with a high glycemic index, such as white bread or bagels, corn flakes and puffed rice, is linked with an increased risk of developing lung cancer, says a study.

Baxalta Incorporated announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of ADYNOVI, an extended circulating half-life recombinant Factor VIII (rFVIII) treatment, for pediatric, adolescent and adult patients with hemophilia A and for use during surgery. Currently licensed in the U.S. as ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] and under regulatory review in Japan, Canada and Switzerland, ADYNOVI is the only rFVIII treatment for hemophilia A developed based on the demonstrated efficacy of ADVATE [Antihemophilic Factor (Recombinant)].

BioMarin Pharmaceutical Inc. announced positive 48-week results from its Phase 1/2 pivotal study for cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (rhTPP1) to treat children with CLN2 disease, a form of Batten disease.  CLN2 disease is a rapidly progressing, fatal neurodegenerative disease with no approved treatments, where the majority of affected children lose their ability to walk and talk by approximately six years of age.

[adsense:336x280:8701650588]

Sangamo BioSciences, Inc. announced the presentation of new preclinical data in disease models from its In Vivo Protein Replacement Platform™ (IVPRP) programs for MPS I (Hurler syndrome) and MPS II (Hunter syndrome). The data demonstrate that the Company's IVPRP approach enabled stable production of therapeutic levels of replacement enzyme from the liver into the circulation and secondary tissues, including the brain, resulting in significant reduction in biomarkers of the disease and, importantly, statistically significant improvements in cognitive function in treated animals.

Sanofi and its specialty care global business unit Sanofi Genzyme presented data from NEO1, its Phase 1/2 clinical study evaluating the investigational novel enzyme replacement therapy neoGAA in 24 patients with late-onset Pompe disease.